NASDAQ · Biotechnology

Cerevel Therapeutics Holdings, Inc. (CERE) Stock

$44.96 +0.74% NASDAQ: CERE Healthcare

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders.

Valuation

MetricValue
Price$44.96
Market Cap$8.19B
P/E Ratio-16.84
P/B Ratio10.81
P/S Ratio0.00
EPS (TTM)$-2.67
52-Week High$44.99
52-Week Low$19.59
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-72.44%
ROA-34.81%
ROCE-38.85%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.71
Current Ratio10.92

Annual Financials (USD)

Metric20192020202120222023
Revenue$0$0$0$0$0
Operating Profit$-83.0M$-149.0M$-220.0M$-368.0M$-447.0M
Net Profit$-128.0M$-152.0M$-222.0M$-352.0M$-433.0M
EPS$-1.01$-1.29$-1.63$-2.32$-2.67
Op Margin—————

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$121.0M$445.0M$689.0M$1.0B$1.2B
Total Liabilities$43.0M$61.0M$110.0M$497.0M$570.0M
Cash$80.0M$384.0M$193.0M$137.0M$991.0M
Borrowings$28.0M$33.0M$37.0M$367.0M$481.0M

Latest News

AMD, Cerebras Strike AI Chip Deals Investor's Business Daily · Jul 22, 2026 Cerebras Systems Sets Date of Second-Quarter 2026 Financial Results GlobeNewswire · Jul 22, 2026 Cerebras Stock Soars on CrowdStrike AI Cybersecurity Deal GuruFocus.com · Jul 22, 2026 CrowdStrike Just Gave Cerebras a Big Vote of Confidence Barrons.com · Jul 22, 2026 Cerebras (CBRS) Stock May Trade At A Premium On AI Expansion Plans Simply Wall St. · Jul 22, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-71.0M$-118.0M$-179.0M$-293.0M$-342.0M
Investing Cash Flow$-2.0M$-38.0M$-447.0M$-393.0M$70.0M
Financing Cash Flow$60.0M$441.0M$424.0M$623.0M$549.0M
Net Cash Flow$-12.0M$304.0M$-191.0M$-59.0M$99.0M
Free Cash Flow$-72.0M$-137.0M$-189.0M$-297.0M$-346.0M

Valuation & Return Ratios

MetricValue
PEG Ratio2.48
EV / EBITDA-18.46
FCF Yield-4.23%
Quick Ratio10.92
Interest Coverage-42.33
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.

Cerevel Therapeutics Holdings, Inc. is headquartered in US.

Cerevel Therapeutics Holdings, Inc. (CERE) stock trades at $44.96 with a market capitalization of $8.19B. The stock is valued at a price-to-earnings (P/E) ratio of -16.84, price-to-book of 10.81, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $19.59 and $44.99, and currently trades at its 52-week high.

On profitability, Cerevel Therapeutics Holdings, Inc. generates a return on equity (ROE) of -72.44%, return on capital employed of -38.85%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cerevel.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides